Testing Times For India’s Drug Patent Law
This article was originally published in PharmAsia News
Executive Summary
NEW DELHI - A couple of ongoing landmark developments, both involving the same drug, are putting India's patent law under a severe test and are expected to decide how multinational pharmaceutical firms will view the Indian market
You may also be interested in...
PharmAsia News India Pharma Roundup: Natco, Strides Arcolab, Glenmark, Ranbaxy/Pfizer, Merck
NEW DELHI - Natco Pharmaceuticals said it is mulling its options after a court decision March 19 to allow Cipla to continue to make and sell Roche's lung cancer drug Tarceva (erlotinib) in India (PharmAsia News, March 20, 2008)
PharmAsia News India Pharma Roundup: Natco, Strides Arcolab, Glenmark, Ranbaxy/Pfizer, Merck
NEW DELHI - Natco Pharmaceuticals said it is mulling its options after a court decision March 19 to allow Cipla to continue to make and sell Roche's lung cancer drug Tarceva (erlotinib) in India (PharmAsia News, March 20, 2008)
Indian Court Allows Cipla to Continue Sales of Generic Roche Lung Cancer Drug Tarceva
MUMBAI - An Indian generic drug maker cannot be halted from manufacturing and selling a generic version of Roche's locally patented lung cancer drug Tarceva (erlotinib) in what a spokesman for the Mumbai-based company said was a "landmark" ruling under the country's three-year-old patent regime